Drug Search Results
More Filters [+]

AES-103

Alternative Names: aes-103, aes103, aes 103
Latest Update: 2024-05-13
Latest Update Note: PubMed Publication

Product Description

The active ingredient in Aes-103 is 5-hydroxymethyl furfural, a naturally occurring small molecule that is chemically related to glucose. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01987908)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AES-103

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hypoxia|Anemia, Sickle Cell

Phase 1: Anemia, Sickle Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Aes-103-003

P2

Terminated

Anemia, Sickle Cell

2015-03-16

2013-001534-18

P2

Completed

Anemia, Sickle Cell

2015-03-16

Aes-103-002

P1

Completed

Anemia, Sickle Cell

2013-06-07

21%

13-4002H

P2

Completed

Hypoxia

2013-06-01

Recent News Events